OCIG Overview
The Ovarian Cancer Innovations Group (OCIG), led by esteemed experts Saketh Guntupalli, MD, and Kian Behbakht, MD, MBA, was established in September 2023 at the University of Colorado Anschutz Medical Campus. Committed to advancing research, prevention, and early detection of ovarian cancer, OCIG brings together a diverse team of researchers, clinicians, and innovators dedicated to combating this disease.
Our Mission
Innovating ovarian cancer early detection and prevention through research, targeted therapies, and public awareness.
Our Vision
We strive to transform ovarian cancer care by pioneering cutting-edge approaches for detection, diagnosis, prevention, and treatment.
Our Approach
OCIG adopts a multipronged approach to studying ovarian cancer:
Enhance Early Detection
Investigating ovarian cancer biomarkers and novel imaging techniques to improve early detection, screening, and patient outcomes.
Predict Disease Recurrence
Developing algorithms to better predict ovarian cancer recurrence.
Tumor Immune Microenvironment Analysis
Investigating the tumor immune microenvironment, including various cells and vessels, to optimize immunotherapy effectiveness in ovarian cancer treatment.
Develop Symptom Screening
Creating a screening tool to identify high-risk individuals based on common ovarian cancer symptoms like bloating, early satiety, urinary tract symptoms, and abdominal pain.
Contact Info
Freda Ireigbe, MHAOCIG Program Manager
13001 East 17th Place
Suite C5010
Aurora, CO 80045
Email: ocig@cuanschutz.edu
Phone: (303) 724-2435
Contact Info
Freda Ireigbe, MHAOCIG Program Manager
13001 East 17th Place
Suite C5010
Aurora, CO 80045
Email: ocig@cuanschutz.edu
Phone: (303) 724-2435